How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

630 results for

Dyspepsia in Pregnancy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

183. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

, pregnancy, pulmonary disease, quality of life, rate control, rhythm control, risks, sinus rhythm, symptoms , and tachycardia-mediated cardiomyopathy. Additionally, the writing committee reviewed documents related to atrial fibrillation (AF) previously published by the ACC and AHA. References selected and published in this document are representative and not all-inclusive. To provide clinicians with a comprehensive set of data, whenever deemed appropriate or when published, the absolute risk difference

2014 American Heart Association

184. Lojuxta (lomitapide) - familial hypercholesterolaemia

[1.52; HAS - Medical, Economic and Public Health Assessment Division 7/13 5.64]; at the end of the study it was 1.896 g/l [1.499, 2.292], a reduction of 40.1% [-51.9, -28.2], p 30%) were: - gastrointestinal problems (diarrhoea, nausea, dyspepsia, etc.) : 93.1% - Infections (flu, nasopharyngitis, gastroenteritis): 58.6% During this study, 6 patients discontinued treatment for adverse effects: 4 for diarrhoea, 1 for headache and 1 for gastroenteritis. 8.2.2. From the SPC According to the SPC (...) : "The most serious adverse reactions during treatment were liver aminotransferase abnormalities observed in 7% des patients. The most common adverse reactions were gastrointestinal effects, reported by 27 (93%) of 29 patients in the Phase 3 clinical trial. Diarrhoea occurred in 79% of patients, nausea in 65%, dyspepsia in 38%, and vomiting in 34%. Other reactions reported by at least 20% of patients include abdominal pain, abdominal discomfort, abdominal distension, constipation, and flatulence

2014 Haute Autorite de sante

185. Antithrombotics: indications and management

disease 28 8.3 Cardiomyopathies and cardiac failure 28 8.4 Mechanical heart valves 28 8.5 Bioprosthetic heart valves 29 8.6 Pregnancy in patients with heart valve disease or prostheses 29 ContentsAntithrombotics: indications and management Antithrombotics: indications and management 9 Primary prophylaxis of vascular disease 30 9.1 Aspirin 30 9.2 Vitamin k antagonists 30 10 Peripheral arterial disease 31 10.1 Antiplatelet agents 31 10.2 Oral anticoagulation 31 10.3 Parenteral anticoagulation 31 10.4 (...) of catheter-related thrombosis 39 14.3 Maintaining patency of arterial and venous catheters 39 15 Pregnancy 40 15.1 Prophylaxis and treatment of venous thromboembolism 40 15.2 Pregnancy failure 40 15.3 Mechanical heart valves 41 15.4 Myeloproliferative disorders 42 16 Models of care 43 17 Provision of information 44 17.1 Sources of further information 44 17.2 Checklist for provision of information to patients starting treatment with vitamin K antagonists 46 18 Implementing the guideline 47 18.1 Resource

2012 SIGN

186. Influence of Aspirin on Human Gut Microbiota Composition and Metabolome

with treatment and sample collection schedule Exclusion Criteria: unfit symptoms, such as epigastric pain, acid reflux, eructation and dyspepsia; diagnosis of any disease during the past 3 months; diarrhea within the previous 7 days; history of alcohol abuse, defined as >80 g/d in men and >40 g/d in women; pregnancy; and mental illness rendering the participants unable to understand the nature, scope, and possible consequences of the study Contacts and Locations Go to Information from the National Library

2018 Clinical Trials

187. Safety Trial of Herbal Melanin in Gastritis Patients

will be examined before and after the administration of Melanole. The results showing a relief of gastritis symptoms for non-H. pylori patients and partial or complete eradication of H. pylori for H.pylori infected patients will be evaluated. Condition or disease Intervention/treatment Phase Acid Dyspepsia Gastritis Other: Herbal Melanin Drug: Nexium Drug: Amoxil Drug: Clarithromycin Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment (...) contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 60 Years (Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Males or Females between 18- 60 years Willing to sign Informed Consent Form (ICF) Women of Child bearing age will be asked to conduct a pregnancy test before enrolling in the study and offered contraceptives for the duration

2018 Clinical Trials

188. Tailored Therapy for Helicobacter Pylori Rescue Treatment

, Layout table for eligibility information Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Participants with non-ulcer functional dyspepsia or scarred peptic ulcer disease Previous failures of H. pylori eradication therapy and need rescue therapy Ability and willingness to participate in the study and to sign and give informed consent Confirmed H. pylori infection Exclusion Criteria: Less than (...) 18 years old With previous gastric surgery Major systemic diseases Pregnancy or lactation Allergy to any of the study drugs Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier

2018 Clinical Trials

189. Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy

this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Participants with penicillin allergy who have non-ulcer functional dyspepsia or scarred peptic ulcer disease Ability and willingness to participate in the study and to sign and give (...) informed consent confirmed H. pylori infection Exclusion Criteria: Patients without penicillin allergy Less than 18 years old With previous gastric surgery Major systemic diseases Pregnancy or lactation Allergy to any of the study drugs Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using

2018 Clinical Trials

190. Rifaximin Improves Gut Dysbiosis in Insulin Resistance and Type 2 Diabetes

questionnaire [ Time Frame: 1 month ] symptomatic improvement in Dyspepsia, distension, abdominal pain Other Outcome Measures: change in weight [ Time Frame: 6 months ] Weight loss in kilograms Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff (...) using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 60 Years (Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: diabetes with gut dysbiosis Exclusion Criteria: recent antibiotic use pregnancy diabetogenic drugs Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research

2018 Clinical Trials

191. Rapid Urease Test for Diagnosis Helicobacter Pylori Infection

citizen Targeted population: Patients of endoscopy centre Cipto Mangunkusumo Hospital Sample: Targeted population who undergo endoscopy examination and met the inclusion and exclusion criteria Criteria Inclusion Criteria: Adult (18-55 years old), Diagnosed with dyspepsia, Indicated for endoscopy, Agreed to participate in the study and signed the informed consent. Exclusion Criteria: Pregnancy and breastfeeding woman, Patients with alarm symptom, History taking of antibiotics (amoxicillin (...) . Some commercial urease tests which are available in Indonesia are Helicotec® and Pronto Dry®. This study aims to determine the effectivity of Helicotec® in diagnosing H. pylori infection. It is expected to be scientific evidence that can be used as the basis daily routine of urease test in diagnosing H. Pylori infection. Condition or disease Helicobacter Pylori Infection Detailed Description: This study is a diagnostic study. There will be 97 dyspepsia patients who met the inclusion and exclusion

2018 Clinical Trials

192. Gluten-related Disorders in Familial Mediterranean Fever Patients

) and not celiac gluten sensitivity (NCGS), that combined seems to affect about 5-10% of the general population. NCGS is the most recent gluten-related disease. It is characterized by intestinal (i.e. irritable bowel syndrome, bloating, dyspepsia) and extra-intestinal symptoms (i.e. fatigue, headache, numbness, mental confusion) related to the ingestion of gluten-containing food, in subjects in whom either celiac disease or wheat allergy previously has been excluded. However, as it is not known what component (...) ) Subjects with Helicobacter pylori infection and other gastrointestinal infection Pregnancy Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03563300 Contacts Layout table for location contacts Contact: Antonio Carroccio, PhD +390916552884 Contact

2018 Clinical Trials

193. A Comparison of Effectiveness of Oral Sucrolfate, Alginate and Hydrotalcide in Dispeptic Pain Treatment

: August 31, 2018 Sponsor: Pamukkale University Information provided by (Responsible Party): Bulent Erdur, Pamukkale University Study Details Study Description Go to Brief Summary: Dyspepsia is a very common but non-specific complaint that may indicate a group of symptoms that can be attributed to the upper gastrointestinal system, such as epigastric discomfort, abdominal bloating or fullness, stomach upset and nausea or vomiting that may be associated with food. This study aimed to improve treatment (...) management of patients with complaints of dyspeptic pain and emergency services, and to compare treatment efficacy of oral sucralfate, alginate and hydrotalcite, which are widely used in our country. Literature According to our research, our study is the first study to compare different antacids in our study of emergency serviste dyspepsia. Condition or disease Intervention/treatment Phase Dyspepsia Drug: Alginate Drug: Sucralfate Drug: Hydrotalcite Phase 4 Detailed Description: This study was performed

2018 Clinical Trials

194. Ibuprofen 4% (w/v) Pivotal Bioequivalence Study

potential with a negative pregnancy test at the screening visit and who were willing to use an effective method of contraception, if applicable (unless of non-childbearing potential or where abstaining from sexual intercourse was in line with the preferred and usual lifestyle of the subject) from first dose until 3 months after the final dose of Investigational Medicinal Product (IMP). Effective forms of contraception included: established use of oral, injected or implanted hormonal methods (...) of contraception, placement of an intrauterine device (IUD) or intrauterine system (IUS), barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, male sterilisation (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate). Female subject of non-child bearing potential with negative pregnancy test at the screening visit. For the purposes of this study, this was defined as the subject being

2018 Clinical Trials

195. A Study to Assess the Absorption of Apixaban (BMS-562247) Sprinkle Capsules Compared With Tablets in Healthy Volunteers

) must have negative serum pregnancy tests (performed at screening and Day 1), must not be breastfeeding, and must agree to follow instructions for method(s) of contraception for duration of treatment with study drug apixaban, and for a total of 33 days after last dose of apixaban. Males sexually active with women of childbearing potential must agree to follow instructions for method(s) of contraception for duration of treatment with study drug apixaban, and for a total of 93 days after the last dose (...) of apixaban; and must be willing to refrain from sperm donation during this time. Body mass index (BMI) of 18.0 to 30.0 kg/m², inclusive. Body mass index = weight (kg)/[height(m)]². Exclusion Criteria: History of chronic headaches (occurring 15 days or more a month) over the previous 3 months. History of gastroesophageal reflux disease, dyspepsia, protracted nausea, or chronic diarrhea. History or evidence of abnormal bleeding or coagulation disorders, hypermenorrhea, intracranial hemorrhage, or abnormal

2018 Clinical Trials

196. High Dose of Dual Therapy Plus Bismuth for Helicobacter Pylori Treatment

deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 80 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Participants with non-ulcer functional dyspepsia or peptic ulcer disease Ability and willingness to participate in the study (...) and to sign and give informed consent Confirmed H. pylori infection Exclusion Criteria: Less than 18 years old With previous gastric surgery Major systemic diseases Pregnancy or lactation Allergy to any of the study drugs Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information

2018 Clinical Trials

197. Serum Creatinine Change / Renal Adverse Effect With Use of Non-steroidal Painkillers in Axial Spondyloarthritis Patients

blood pressure > 140 mm Hg and/ or diastolic blood pressure >90 mm Hg or on anti-hypertensive drug Dyspepsia or active peptic ulcer disease : upper abdominal discomfort or upper abdominal pain related with food or peptic ulcer disease diagnosed by upper gastrointestinal endoscopy Diabetes mellitus: abnormal random plasma glucose or diagnosed case of diabetes mellitus Ischemic heart disease: history of angina or ECG changes suggestive of ischemic heart disease Active congestive heart failure: pedal (...) edema with tender hepatomegaly with raised JVP or diastolic dysfunction on echocardiography Asthma: diagnosed case of asthma or rhonchi on chest auscultation Bleeding problems: having a history of prolonged bleeding Pregnancy: missed period followed by positive pregnancy test Simultaneous use with certain medications such as warfarin, phenytoin, cyclosporine, probenecid, lithium, digoxin, ACE inhibitor, thiazide Contacts and Locations Go to Information from the National Library of Medicine To learn

2018 Clinical Trials

198. Trauma Acute Pain Treatment With Methoxyflurane Vaporized (PENTHROX®): Efficacy and Safety Study (MEDITA)

ones will be calculated. Incidence of treatment-emergent pregnancy [ Time Frame: From baseline up to 16 days later. The follow-up until delivery is out from the scope of the trial. ] Pregnant patients or suspected to be pregnant are excluded from the trial. In case of occurrence the pregnancy will be recorded and followed up until delivery for pharmacovigilance purposes. Incidence of investigational medicinal drug misuse/abuse [ Time Frame: From baseline up to 30 minutes later or to the end (...) of the same vehicle, motor vehicle / pedestrian or cyclist impact with a motor vehicle in motion, projection / overturn, fall from a height of> 3 meters, extraction on event place > 20 min). Altered level of vigilance and / or conscience (GCS <15) Symptomatic hypotension or Systolic Pressure <100 mm / Hg Discomfort with Respiratory Rate > 20 and Oxygen Saturation <95% Known pregnancy status.Note: a 1 day delay with respect to the planned menstruation date (28days since the beginning of the previous one

2018 Clinical Trials

199. A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area

clinical trial during the study period. Agrees to complete all study visits and procedures. Agrees not to donate blood to a blood bank for 12 months after receiving the last vaccine. Exclusion Criteria: Women who are pregnant or lactating or have a positive urine pregnancy test at screening or on the day of vaccinations. Note: all women presenting for screening will have urine pregnancy testing. "Females of childbearing potential must agree to use an efficacious hormonal or barrier method of birth (...) : this may include, but is not limited to: abdominal pain or cramps, loss of appetite, nausea, general ill-feeling or vomiting. Moderate or severe diarrheal illness* during the 6 weeks prior to enrollment. *Note: Moderate or severe diarrheal illness is defined by the passage of > / = 4 unformed or loose stools (mix of liquid and solid components) in a 24 hour period History of chronic gastrointestinal illness*. *Note: this includes severe dyspepsia or gastroesophageal reflux disease, constipation

2018 Clinical Trials

200. Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revitaâ„¢ System in Treatment of Type 2 Diabetes

symptoms Known history of a structural or functional disorder of the stomach including gastroparesis, gastric ulcer, chronic gastritis, gastric varices, hiatal hernia (> 2 cm), cancer or any other disorder of the stomach Known history of chronic symptoms suggestive of a structural or functional disorder of the stomach, including any symptoms of chronic upper abdominal pain, chronic nausea, chronic vomiting, chronic dyspepsia or symptoms suggestive of gastroparesis, including post-prandial fullness (...) ) Uncontrolled hyperglycemia with a glucose level >270 mg/dl (>15 mmol/L) after an overnight fast or >360 mg/dl (>20 mmol/l) in a randomly performed measurement during Medication Run-In Period and confirmed by a second measurement (not on the same day) Mean of 3 separate blood pressure measurements >180 mmHg (systolic) or >100 mmHg (diastolic) WOCBP with a positive urine pregnancy test at Baseline Visit Active and uncontrolled GERD defined as grade III esophagitis or greater Abnormalities of the GI tract

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>